Prevention of Healthcare Associated Infections in Bone Marrow Transplant Patients

NCT02463214 | Completed

• 1 other identifier: H15-00662
• Study Type: interventional
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

This study involves sampling bone marrow transplant patients, hospital workers and the patient room for microbes using swabs and other techniques. We send these samples to the laboratory, where they will use state-of-the art technology to identify and relate the microbes to each other. This study also involves putting copper, nickel, or titanium into some hospital rooms, and seeing whether these metals influences the growth of microbes. Some equipment in the hospital room, such as faucets and soap dispensers will be replaced by sensor-based (e.g. touchless) controls.

Conditions

Transplantation Infection

Outcome Measures

Primary Outcomes (1)

• Change in bioburden on surfaces

  Looking to see the effectiveness of copper and titanium on the microbiota in the environment of the recovery room.

  up to 28 days

Study Arms (2)

Standard Room

NO INTERVENTION

Standard bone marrow transplant recovery, single occupancy, room

Engineered Room

EXPERIMENTAL

Single occupancy bone marrow transplant recovery room, engineered with touchless devices, and surfaces coated with either copper or titanium dioxide.

Other: Engineered Room

Interventions

Engineered Room OTHER

Touchless devices: Hand sanitizers, faucets, paper towel dispensers, call devices, Ultraviolet C Aseptix™ Disinfection devices above bathroom doors Copper products: Room and bathroom entrance door hardware, over bed table and bed side table surfaces, chair metal arms, wardrobe handles and knobs, weigh scale, sinks, grab bars, light switch panels, toilet flush handles, faucets and handles, patient bed rails. Titanium dioxide paint: Room walls, head walls, light switches, bathroom wall shelves, toilet tank and bowl, head wall unit fixed equipment, television remote and Bed Control remote

Engineered Room

Eligibility Criteria

• Age: 19 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• undergoing allogenic bone marrow transplant for acute myeloid leukemia
• will be admitted to the leukemia and bone marrow transplant service at Vancouver General Hospital
• admission to the ward anticipated to be approximately 28 days

You may not qualify if:

• allergies to copper, nickel or titanium
• patients admitted for stays anticipated to be less than 28 days
• undergoing allogenic bone marrow transplant for acute myeloid leukemia
• caring for patient enrolled in the study as a primary nurse
• allergies to copper, nickel or titanium

Sponsors & Collaborators

• University of British Columbia: lead
• Vancouver Coastal Health Research Institute: collaborator

Study Sites (1)

Vancouver General Hospital

Vancouver, British Columbia, V5Z 1M9, Canada

Location

Study Officials

• Linda Hoang, MD FRCPC

  The University of British Columbia

  PRINCIPAL INVESTIGATOR

• Elizabeth Bryce, MD FRCPC

  The University of British Columbia

  PRINCIPAL INVESTIGATOR

• Patrick Tang, MD PhD FRCPC

  Sidra Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Medical Microbiologist, BC Centre for Disease Control

Study Record Dates

• First Submitted: June 2, 2015
• First Posted: June 4, 2015
• Study Start: September 1, 2015
• Primary Completion: March 1, 2018
• Study Completion: March 1, 2018
• Last Updated: April 17, 2019

Record last verified: 2019-04

Locations

CA (1)